Management of type 2 diabetic nephropathy (DMN) was once considered the sole responsibility of endocrinologists. In the early years, patients who suffered from DMN either died prematurely due to cardiovascular complications, or from concurrent advanced diabetesrelated end-organ damage. As a result of the high morbidity and mortality and the poor quality of life, these patients were less likely to be advised dialysis treatment when they reached end-stage renal disease (ESRD).
Predialysis management in diabetic patients with chronic renal insufficiency (CRI)
While endocrinologists tend to focus on the management of early diabetes mellitus and the prevention of diabetes-related complications, nephrologists tend to focus mainly on the dialysis aspect of therapy. The "predialysis period", the "no-man's land", is considered to be merely a period for "dialysis planning". In reality, the progression of CRI to ESRD is a continuum of disease and the pre-dialysis period is actually a very critical period that deserves more proper attention if the outcome of dialysis is to be improved. Unfortunately, the importance of pre-dialysis care of diabetic patients is often, if not always, neglected and habitually inadequate (5) . This is further aggravated by the problems of late referrals and diagnosis. Multiple comorbidity conditions of diabetic patients are often blamed as the reason for their unfavorable outcome despite optimization of the dialysis therapy. In fact, many of these complications are seen early before the commencement of any dialysis treatment. As a matter of fact, the pre-dialytic period is the most vulnerable period for the development of malnutrition, left ventricular hypertrophy (LVH), uncontrolled blood pressure, hypo-or hyperglycemia, acidosis and calcium/phosphate disturbances. Abundant data now suggest that baseline parameters at the onset of dialysis do bear a prognostic role in the outcome of dialysis therapy (5) (6) (7) . This situation is especially true in the diabetic populations since such patients are prone to comorbidity conditions. The latter, once developed, usually run a relentless course.
The artificial segregation of patients from a CRI status to an ESRD status, and the abrupt transition from an endocrinologist's care to a nephrologist's care, may not be an optimal model of care for diabetic patients with progressive nephropathy. This undesirable situation often leads to fragmentation of care and incompleteness of management. The tendency of certain specialists to overemphasize one aspect of treatment while neglecting the other aspects is common. As seen in Figure 1 , the management of diabetic patients with CRI is a continuous and evolving process which involves multiple levels and disciplines of care. An integrated model that involves various specialties with emphasis on different aspects at different stages of the disease should be the optimal model of care for these patients. kappa b (NF-KB), protein kinase C, reactive oxygen species (ROS), transforming growth factor-beta (TGF-ß), vascular endothelial growth factor (VEGF), and formation of advanced glycation end-products (AGE)). Many of these agents are now known to play important roles in the pathogenesis of diabetes-related (especially cardiovascular) complications. The UKPDS trial has confirmed that hyperglycemia is the single main cause of diabetic complications and it is now a standard that an HbA1c value of <7% should be achieved to prevent diabetesrelated complications (8) .
In the past, when advanced diabetes-related complications had developed, the importance of stringent diabetic control would be questioned, with concern for an increased risk for developing hypoglycemia. Recent evidence has shown that a stringent glycemic control throughout the course of diabetes mellitus is important in determining the outcome of these patients while being maintained on dialysis. Previous study has demonstrated that a poor glycemic control at the pre-dialysis period (HbA1c >10%) is associated with an increase in mortality in type 2 diabetes patients treated with maintenance hemodialysis, and the effect persists for up to 5 years in the post-dialysis period (6) .
Other studies have also suggested that HbA1c levels in diabetic dialysis patients are correlated with survival (9) . Although there is no clear evidence that a strict glycemic control (HbA1c < 7%) is beneficial to uremic diabetic patients, it is now generally accepted that, for these patients, HbA1c levels should be kept below 7% to aim for the maintenance of a state of euglycemia (10) .
Insulin requirement
As renal failure progresses, more patients will receive insulin therapy either because of secondary oral hypoglycemic agent (OHA) failure or because of unsuitability of OHA usage in the presence of significant renal function impairment. There have been relatively few studies examining the determinants of glucose metabolism in uremic patients. Factors such as ß-cell function, endogenous metabolism and elimination of insulin, insulin sensitivity, body size and carbohydrate intake all interact to influence insulin requirement in diabetic patients. As renal failure progresses, exogenous insulin requirement often decreases. This phenomenon is believed to be secondary to the reduction in renal clearance of insulin and to the progressive loss of appetite and body weight. However, previous studies have failed to show a difference in basal insulin levels between diabetic patients with and without renal failure (11) . A contributing mechanism could be the accumulation of C-peptide in CRI. When co-administrated with insulin, C-peptide has been shown to improve metabolic control in diabetic patients (12) . On the other hand, uremia per se is associated with an insulin-resistant state which is caused by a decrease in the insulin-stimulated uptake of glucose by muscle (13) . Moreover, ß-cell function deteriorates with time, resulting in an increment in insulin requirement (11) .
In those patients with renal failure who develop a high insulin-resistance state, administration of supraphysiologic doses of insulin may be detrimental. Indeed, it has been suggested that insulin therapy may increase blood pressure and hyperinsulinemia is pro-atherosclerotic in type 2 diabetic patients (14) . Conventional insulin sensitizer (e.g., biguanides) therapy is contraindicated in patients with renal failure due to the potential risk of acidosis. The new anti-diabetic agent, thiazolidinedione, is a member of a class of peroxisome proliferator-activated receptor modulators (PPAR) which can ameliorate insulin resistance in type 2 DM patients by increasing peripheral insulin sensitivity. This action leads to an improvement in insulin-mediated glucose disposal and hence a reduction in insulin requirements (15) . PPAR-gamma modulators may bring about potential benefits in atherosclerotic diseases due to their effect on vascular cell proliferation (16) . The pharmacokinetics of these modulators is unaltered by renal function impairment. Newer agents such as rosiglitazone and pioglitazone have not been reported to induce hepatotoxicity. These features render the thiazolidinedione group a potential role in glycemic control of type 2 diabetes patients with CRI. We have also shown that rosiglitazone is well tolerated and useful in improving insulin sensitivity in uremic type 2 diabetic patients (17) .
Anemia
Some cohort studies observed that anemia tended to be more severe in diabetic patients than in non-diabetic patients (18) . It is also noted that anemia occurs at a very early stage of DMN. Several mechanisms may lead to anemia in diabetic patients. The latter are prone to fluid overload and hence dilutional anemia. It is also postulated that inadequate erythropoietin secretion in response to hypoxic stimulation can occur due to the presence of autonomic neuropathy, based on the finding in animal studies that renal denervation interferes with erythropoietin response to hypoxia (19) .
Chronic anemia, though apparently asymptomatic, can cause detrimental structural and hemodynamic changes to the cardiovascular system. The association between anemia and cardiovascular complications including LVH and CHF, has been consistently demonstrated in the nonuremic, pre-dialysis and dialysis populations (20) . Anemia is also associated with a decreased quality of life and an increased hospitalization rate of CRI patients. Chronic anemia triggers compensatory mechanisms (increases in sympathetic activity and in cardiac output) and the secondary hypoxic insult can also upregulate the reninangiotensin system leading to volume expansion and hypertension. These latter complications aggravate the progression of LVH.
Foley et al have demonstrated that echocardiographic abnormalities including LVH, LV dilatation and systolic dysfunction are highly prevalent at the time of dialysis initiation (21) . The potential benefit of correction of anemia in CRI patients has previously been studied. Several small studies have demonstrated the improvement in cardiac parameters with correction of anemia, including regression of LVH and improvement of CHF (22) . These effects become less prominent in those already on dialysis (23), presumably due to the delay in intervention. Correction of anemia at the pre-dialysis period might be of prime importance in the improvement of the cardiovascular outcome of diabetic patients. However, further studies and cost analysis are required to determine the optimal timing and target of anemia therapy.
Hypertension
Hypertension is an immensely important comorbidity of DMN. Previous studies have shown that each 10-mmHg decrease in systolic blood pressure (BP) can reduce the risk for myocardial infarction by 10%. Hypertension in diabetes is characterized by sympathetic hyperactivity, salt-and volume-sensitivity and over-expression of the renin-angiotensin-aldosterone system. As renal function deteriorates, the role of salt-intake and volume control becomes more prominent in blood pressure control. Salt restriction can lead to the regression of left ventricular hypertrophy, the improvement of proteinuria, and the enhancement of antihypertensive effects of antihypertensive drugs. Appropriate salt and fluid restriction along with proper usage of diuretics is important in blood pressure control in these patients.
The standard definition of hypertension is a BP of > 140/90 mmHg. Recent studies have suggested that the relationship between blood pressure levels and hypertensive-related complications is a continuum (24) . It is recommended that a lower BP of 130/80 mmHg should be the cut-off point for defining hypertension in diabetic patients. Under-treatment of hypertension is common in type 2 diabetic patients and might partly be due to the difficulty of BP control in this particular group of patients. The first line anti-hypertensive drugs should be angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin-receptor antagonists (25) . The benefit of renin-angiotensin system (RAS) inhibition in diabetic patients probably extends beyond its renoprotective effect. In the HOPE study, ACE-I reduced cardiovascular mortality of high risk patients including diabetic patients with mild CRI (26) . Diabetic patients with CRI have increased circulating serum ACE levels, which may have adverse effects on the cardiovascular system (27) . However, one needs to be cautious about the potential risk of hyperkalemia and type IV renal tubular acidosis. As renal function deteriorates, monotherapy is rarely adequate. Combination treatment employing betablockers, diuretics and ACE-I are the preferred choices in view of the pathophysiology of hypertension in DMN. However, in reality, calcium channel blockers or vasodilators (e.g., hydralazine) are frequently required for adequate BP control. Reaching the targeted level of BP and avoidance of fluid overload are probably more important than the choice of individual anti-hypertensive drugs during the late stages of renal disease.
Calcium/phosphate disturbances
Calcium/phosphate disturbance is common in newly referred CRI patients. Most of them are not adequately treated. Disturbances in calcium/phosphate balance in the face of renal failure will aggravate parathyroid hyperplasia, which is associated with hypertension and LVH (28) . It is recommended that vitamin D should be used to prevent parathyroid hyperplasia even in patients with mild to moderate CRI. However, diabetic patients are less likely to develop hyperparathyroid bone disease or parathyroid hyperplasia. Instead, they are more prone to adynamic bone disease resulting from impairment of parathyroid hormone secretion. This impairment in secretion is believed to be partly due to the inhibiting effect of advanced glycation end-products (AGE) (29) . It is interesting to note that diabetic patients have lower bone turnover than their non-diabetic counterparts even in the absence of renal insufficiency (30) . Nevertheless, adequate control of calcium/phosphate metabolism is still of vital importance in the management of diabetic renal failure. Elevated serum phosphorus levels and, hence, high serum calcium x phosphorus product values are independent risk factors for coronary artery calcification and calciphylaxis. Both of the latter complications are more common in diabetic patients and are likely to become irreversible once they occur.
Malnutrition
Diabetic patients on dialysis are at high risk of developing malnutrition, which is an independent adverse factor for the outcome of dialysis. Although dietary protein restriction has been advocated to slow down the progression of renal failure in diabetic patients (31) , its benefit has to be weighted against its potential harm. Other studies have suggested that severe dietary protein restriction in overt DMN does not delay the progression of renal disease, but may actually induce malnutrition (32, 33) . The effect of protein restriction is also equivocal in non-diabetic renal patients (34) . If low protein diet is prescribed, it is important to monitor the nutritional status and dietary compliance closely. During the advanced stages of diabetic renal failure, delaying the onset of dialysis at the expense of malnutrition should be avoided. Diabetic patients, especially the elderly group, are at a high risk for malnutrition. The loss of muscle bulk and body weight may be masked by the presence of edema, and the fall of serum creatinine value as a result of plasma dilution, may be interpreted as improvement in renal function. Diabetic patients are often left with a low calorie, low protein, low phosphate, low salt and low potassium diet. Such a diet tends to limit choices. In addition, decreased intakes are further aggravated by anorexia and the symptoms of esophageal dysmotility and gastroparesis.
Metabolic acidosis
Metabolic acidosis is highly prevalent among patients with CRI and is reported to be as high as 23% in newly referred CRI patients. It is estimated that for patients with mild to moderate renal insufficiency (serum creatinine levels of 2 to 4 mg/dL), the serum total carbon dioxide levels may fall by 25%. Apart from the accumulation of endogenous acids in excess of the kidney's capacity to excrete them, patients with diabetic nephropathy are prone to develop hyporeninemic hypoaldosteronism early in their course of disease. Surprisingly, in a study where 113 predialysis patients (creatinine clearance <30 mL/min) were examined, diabetic patients were found to have less severe metabolic acidosis than non-diabetic patients due to unknown mechanisms (35) .
Nevertheless, laboratory and clinical data have suggested that metabolic acidosis is detrimental to the body by aggravating protein catabolism, bone loss and hyperkalemia. Severity of acidosis correlates with nutritional parameters (36) and correction of even mild metabolic acidosis with oral sodium bicarbonate therapy can improve nutritional parameters in pre-dialysis and dialysis patients (37) . Although asymptomatic, mild metabolic acidosis in CRI is worth correcting unless the resultant extra sodium load cannot be well tolerated.
CONCLUSION
Despite advances in dialysis therapy and in the management of cardiovascular diseases, the pessimistic prospect of diabetic patients on dialysis has not been altered. It is believed that DMN patients with CRI are in their most vulnerable period to develop myriad complications which commonly run a ruthless course and extend into the dialysis period. Early recognition and aggressive intervention in complications during the predialysis period when these complications are still at a subclinical stage of development, could be the missing link for better outcomes of diabetic patients on dialysis. Failure of medical therapy to control these complications adequately is an indication for prompt commencement of dialysis. As diabetic patients will inevitably become the biggest sector of the dialysis population in the future, better knowledge and greater effort are needed to improve the care and prognosis of these patients. Improvement measures will also help to reduce the burden of the disease in the long term as dialysis has already imposed significant healthcare costs not only in the developed but also in the developing parts of the world (4).
